Journal of Clinical Oncology, Vol 5, 1933-1941, Copyright © 1987 by American Society of Clinical Oncology
In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy
JH Phillips, BT Gemlo, WW Myers, AA Rayner and LL Lanier
Becton Dickinson Monoclonal Center, Inc, Mountain View, CA.
Patients with advanced metastatic cancer were given combined autologous
lymphokine activated killer (LAK) cell and recombinant interleukin-2
(rIL-2) therapy on a National Cancer Institute extramural phase II trial.
Systemic administration of rIL-2 resulted in pronounced lymphocytopenia.
Within two days after completion of in vivo rIL-2 therapy, there was a
dramatic increase in absolute numbers of circulating lymphocytes, and
cytotoxic activity against tumor cell targets was mediated by peripheral
blood lymphocytes, indicating in vivo generation of LAK activity. Patients
were leukapheresed and cells cultured for three to four days in rIL-2.
rIL-2 cultured cells from all patients demonstrated cytotoxic activity. In
order to characterize the effector cell, T cells and natural killer (NK)
cells were isolated to greater than 95% purity by flow cytometry. Cytotoxic
activity was mediated by rIL-2--activated NK cells, whereas T cells
demonstrated no substantial activity. The circulating in vivo cytotoxic
effectors detected after in vivo rIL-2 therapy were also shown to be
rIL-2-- activated NK cells. Results from these studies demonstrate that all
patients were capable of generating a cytotoxic response, and that the
cytotoxic effector cells were rIL-2--activated NK cells, identified by the
phenotype CD3--, Leu 19+.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Margolin, M. B. Atkins, J. P. Dutcher, M. S. Ernstoff, J. W. Smith II, J. I. Clark, J. Baar, J. Sosman, J. Weber, C. Lathia, et al.
Phase I Trial of BAY 50-4798, an Interleukin-2-Specific Agonist in Advanced Melanoma and Renal Cancer
Clin. Cancer Res.,
June 1, 2007;
13(11):
3312 - 3319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.A. Sosman, P. Stiff, S.M. Moss, P. Sorokin, B. Martone, R. Bayer, K. van Besien, S. Devine, W. Stock, D. Peace, et al.
Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Post-Stem-Cell Infusion
J. Clin. Oncol.,
February 1, 2001;
19(3):
634 - 644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Porgador, O. Mandelboim, N. P. Restifo, and J. L. Strominger
Natural killer cell lines kill autologous beta 2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy
PNAS,
November 25, 1997;
94(24):
13140 - 13145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Schantz, G. Clayman, T. Racz, E. A. Grimm, F. J. Liu, P. Lavedan, D. Taylor, C. Pellegrino, and H. Savage
The In Vivo Biologic Effect of Interleukin 2 and Interferon Alfa on Natural Immunity in Patients With Head and Neck Cancer
Arch Otolaryngol Head Neck Surg,
November 1, 1990;
116(11):
1302 - 1308.
[Abstract]
[PDF]
|
|
|
|
